A Phase 2 Study of Olaparib in combination with pembrolizumab in participants with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD)-positive advanced cancer

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date28/10/19 → 27/10/24

Keywords

  • clinical trial
  • treatment efficacy
  • DNA repair
  • DNA damage

Clinical Trial Phase

  • Phase II